Report
Valens Research

ENTA - Embedded Expectations Analysis - 2020 04 03

 Enanta Pharmaceuticals, Inc. (ENTA:USA) currently trades below historical averages relative to UAFRS-based (Uniform) assets, with a 1.4x Uniform P/B. At these levels, the market has bearish expectations for the firm, and management may be concerned about their RSVP study, EDP-297, and EDP-514

 Specifically, management may have concerns about the success of their RSVP study on RSV progress and symptoms and the success of EDP-938's Phase 2 study for pediatric patients. In addition, they may have concerns about their ability to develop EDP-297 as more than just a super potent EDP-305 and about expected royalties. Moreover, they may have concerns about the usefulness of the EP-514 rodent study and their ability to further build cash. Furthermore, they may be exaggerating the superiority of EDP-297 compared to other FXR agonists
Underlying
Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals is a biotechnology company that creates small molecule drugs primarily for the treatment of viral infections and liver diseases. The company's wholly owned research and development programs are in virology, namely respiratory syncytial virus and hepatitis B virus, and in liver disease (non-virology), namely non-alcoholic steatohepatitis and primary biliary cholangitis. Through its Collaborative Development and License Agreement with AbbVie Inc (AbbVie), the company has discovered and out-licensed to AbbVie two protease inhibitor compounds that have been clinically tested, manufactured, and commercialized by AbbVie for the treatment of hepatitis C virus.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch